<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01190878</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-303-001</org_study_id>
    <nct_id>NCT01190878</nct_id>
  </id_info>
  <brief_title>Study to Compare Differing Dosing Regimens of ISV-303 (Bromfenac in DuraSite) to Xibrom and Vehicle in Post Cataract Surgery Volunteers</brief_title>
  <official_title>A Randomized Double-masked 14-day Study to Compare the Ocular Safety, Tolerability, and Efficacy of Differing Dosing Regimens of ISV-303 to Vehicle and Xibrom™ in Post Cataract Surgery Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSite Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSite Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy in
      topical administration of differing dosing regimens of ISV-303 compared to vehicle and
      Xibrom™ when dosed for 2 weeks in post-cataract-surgery volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Inflammation</measure>
    <time_frame>15 days</time_frame>
    <description>Anterior Chamber Cell Grade 0 at Day 15 measured on a 0 to 4 scale: &quot;0&quot; is 0 cells; &quot;1&quot; is 1-10 cells; &quot;2&quot; is 11-20 cells; &quot;3&quot; is 21-50 cells; &quot;4&quot; is &gt; 50 cells.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Ocular Inflammation</condition>
  <arm_group>
    <arm_group_label>ISV-303 BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ISV-303 QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Xibrom BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DuraSite Vehicle BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV-303</intervention_name>
    <description>0.075% of bromfenac in DuraSite dosed QD</description>
    <arm_group_label>ISV-303 QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV-303</intervention_name>
    <description>0.075% of bromfenac in DuraSite dosed BID</description>
    <arm_group_label>ISV-303 BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DuraSite Vehicle</intervention_name>
    <description>Vehicle dosed BID</description>
    <arm_group_label>DuraSite Vehicle BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xibrom™</intervention_name>
    <description>0.09% bromfenac dosed BID</description>
    <arm_group_label>Xibrom BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for unilateral cataract surgery (phacoemulsification or extracapsular
             extraction) with posterior chamber intraocular lens implantation on the day prior to
             study enrollment

          -  Meet the best corrected visual acuity score requirement

          -  Meet the IOP requirement

          -  Additional inclusion criteria also apply

        Exclusion Criteria:

          -  Known hypersensitivity or poor tolerance to bromfenac sodium or any component of the
             study medications or any of the procedural medications

          -  Use of any ocular topical, or systemic medication that could interfere with normal
             lacrimation, wound healing, the test agent, or the interpretation of study results,
             within 1 week prior to Day of Surgery

          -  Additional exclusion criteria also apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>August 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2010</study_first_posted>
  <results_first_submitted>April 26, 2016</results_first_submitted>
  <results_first_submitted_qc>June 2, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 13, 2016</results_first_posted>
  <disposition_first_submitted>January 26, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>January 27, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 31, 2012</disposition_first_posted>
  <last_update_submitted>June 2, 2016</last_update_submitted>
  <last_update_submitted_qc>June 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ISV-303 BID</title>
          <description>ISV-303: 0.075% bromfenac in DuraSite dosed BID</description>
        </group>
        <group group_id="P2">
          <title>ISV-303 QD</title>
          <description>ISV-303: 0.075% bromfenac in DuraSite dosed QD</description>
        </group>
        <group group_id="P3">
          <title>Xibrom BID</title>
          <description>Xibrom™: 0.09% bromfenac dosed BID</description>
        </group>
        <group group_id="P4">
          <title>DuraSite Vehicle BID</title>
          <description>DuraSite Vehicle: Vehicle dosed BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="42"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>ISV-303 BID</title>
          <description>ISV-303: 0.075% of Bromfenac in DuraSite Dosed BID</description>
        </group>
        <group group_id="B2">
          <title>ISV-303 QD</title>
          <description>ISV-303: 0.075% of Bromfenac in DuraSite Dosed QD</description>
        </group>
        <group group_id="B3">
          <title>Xibrom BID</title>
          <description>Xibrom™: Xibrom dosed BID</description>
        </group>
        <group group_id="B4">
          <title>DuraSite Vehicle BID</title>
          <description>DuraSite Vehicle: Vehicle Dosed BID</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="42"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="169"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.3" spread="7.70"/>
                    <measurement group_id="B2" value="70.9" spread="9.75"/>
                    <measurement group_id="B3" value="68.6" spread="10.49"/>
                    <measurement group_id="B4" value="67.0" spread="9.30"/>
                    <measurement group_id="B5" value="69.5" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51-70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Inflammation</title>
        <description>Anterior Chamber Cell Grade 0 at Day 15 measured on a 0 to 4 scale: &quot;0&quot; is 0 cells; &quot;1&quot; is 1-10 cells; &quot;2&quot; is 11-20 cells; &quot;3&quot; is 21-50 cells; &quot;4&quot; is &gt; 50 cells.</description>
        <time_frame>15 days</time_frame>
        <population>Intent-to-Treat (ITT) Population using Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>ISV-303 BID</title>
            <description>ISV-303: 0.075% of Bromfenac in DuraSite Dosed BID</description>
          </group>
          <group group_id="O2">
            <title>ISV-303 QD</title>
            <description>ISV-303: 0.075% of Bromfenac in DuraSite Dosed QD</description>
          </group>
          <group group_id="O3">
            <title>Xibrom BID</title>
            <description>Xibrom™: Xibrom dosed BID</description>
          </group>
          <group group_id="O4">
            <title>DuraSite Vehicle BID</title>
            <description>DuraSite Vehicle: Vehicle Dosed BID</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Inflammation</title>
          <description>Anterior Chamber Cell Grade 0 at Day 15 measured on a 0 to 4 scale: &quot;0&quot; is 0 cells; &quot;1&quot; is 1-10 cells; &quot;2&quot; is 11-20 cells; &quot;3&quot; is 21-50 cells; &quot;4&quot; is &gt; 50 cells.</description>
          <population>Intent-to-Treat (ITT) Population using Last Observation Carried Forward (LOCF) method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="45"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>29 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ISV-303 BID</title>
          <description>ISV-303: 0.075% of Bromfenac in DuraSite Dosed BID</description>
        </group>
        <group group_id="E2">
          <title>ISV-303 QD</title>
          <description>ISV-303: 0.075% of Bromfenac in DuraSite Dosed QD</description>
        </group>
        <group group_id="E3">
          <title>Xibrom BID</title>
          <description>Xibrom™: Xibrom dosed BID</description>
        </group>
        <group group_id="E4">
          <title>DuraSite Vehicle BID</title>
          <description>DuraSite Vehicle: Vehicle Dosed BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>InSite Vision</organization>
      <phone>510-747-1269</phone>
      <email>jhutcheson@insitevision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

